Pulmonary Arterial Hypertension Market by Drug Classes (Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, and Soluble Guanylate Cyclase Stimulators), and Pipeline Analysis of Clinical 1, 2, and 3 Drugs and Forecast 2017-2021

Pulmonary Arterial Hypertension Market by Drug Classes (Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, and Soluble Guanylate Cyclase Stimulators), and Pipeline Analysis of Clinical 1, 2, and 3 Drugs and Forecast 2017-2021

Pulmonary arterial hypertension (PAH) is a challenging disease to diagnose accurately as it requires invasive investigations and significant experience to manage patients effectively. Pulmonary arterial hypertension is a progressive disorder, characterized by high blood pressure in pulmonary arteries, which carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. However, there are treatments available in the market that can help patients manage the symptoms of PAH. Prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5), and soluble guanylate cyclase (sGC) stimulators are the major classes of drugs that are used to manage PAH symptoms. The PAH treatment may include pills such as  ambrisentan (Letairis), bocentan (Tracleer), macitentan (Opsumit), riocigaut (Adempas), selexipag (Uptravi), sildenafil (Revatio), tadalafil (Adcirca), treprostinil (Orenitram); inhalers such as Iloprost tromethamine (Ventavis), treprostinil (Tyvaso); and intravenous drugs such as epopostenol sodium (Flolan, Veletri), treprostinil.

The global pulmonary arterial hypertension market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug classes (endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase stimulators), pipeline analysis of clinical 1, 2, and 3 drugs, and forecasts growth trends (CAGR% – 2017 to 2021).

The global pulmonary arterial hypertension market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global pulmonary arterial hypertension market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global pulmonary arterial hypertension market and included in this report are Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Pulmonary Arterial Hypertension (PAH) Market

1. Drug Class
1.1. Endothelin Receptor Antagonists (ERAs)
1.2. Phosphodiesterase-5 (PDE-5) Inhibitors
1.3. Prostacyclin and Prostacyclin Analogs
1.4. Soluble Guanylate Cyclase (sGC) Stimulators

2. Clinical Pipeline Analysis
2.1. Phase 3 Drugs
2.2. Phase 1 and 2 Drugs

3. Company Profiles
3.1. Actelion Pharmaceuticals, Ltd.
3.2. Bayer HealthCare
3.3. Gilead Sciences, Inc.
3.4. GlaxoSmithKline plc.
3.5. Novartis AG
3.6. Pfizer, Inc.
3.7. United Therapeutics Corporation

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish